Why Formulate the Question First?
A method comparison can produce a large table of results and still fail to answer a useful question. “Which multi-omics method performs best?” leaves open what “best” means, which methods count as competitors, what kinds of data matter, and who is expected to use the conclusion. A benchmark question makes those choices explicit before results are known. It is the anchor for a fair and interpretable comparison, not a substitute for the later choices about performance measures or simulation design.
The question should describe a practical comparison at the level needed to guide its design. It names the methods or method classes, the target data conditions, the scientific task, and the intended audience. These elements work together: a conclusion about methods for prioritizing shared molecular signals in complete, small-sample cohorts need not apply to predicting outcomes when a modality is often missing.
A useful question is specific enough that two independent teams could agree on whether a proposed comparison addresses it. It is also bounded: it does not promise to rank every method for every possible data set. “Which of methods A and B better recovers known shared pathway signals in cohorts with moderate sample size and all three modalities measured, for investigators choosing a discovery workflow?” is much more informative than “Which integration method is best?”
The Four Parts of a Benchmark Question
Start by writing four components in plain language. The method list should identify named methods and, when relevant, their prespecified versions or allowed configurations. The data conditions should describe the target domain rather than a convenient data set alone: examples include sample-size range, modality coverage, feature dimension, dependence structure, and cohort or batch variation. The scientific task should say what the methods are being asked to do, such as classify an outcome, prioritize candidate features, or recover a known shared signal. The audience identifies the decision the findings are intended to support.
| Component | Question to answer | Example of useful specificity |
|---|---|---|
| Methods | Which procedures are in scope? | Two named integration methods and a prespecified single-modality baseline |
| Target data conditions | For what kinds of data should conclusions be relevant? | Small cohorts with RNA and protein measurements and moderate cross-omics dependence |
| Scientific task | What output or scientific objective is being compared? | Ranking features that carry a known shared disease signal |
| Audience | Whose decision should the evidence inform? | Researchers selecting a discovery workflow before collecting a larger cohort |
The audience is not decoration. A method developer may need evidence about stability across difficult conditions; a laboratory investigator may need to know whether a workflow can operate with the assays routinely available. The same comparison can be relevant to both, but its conclusions and limitations should be framed for the decision actually at stake.
State assumptions that connect these elements. Methods should receive comparable information unless access to different information is itself the subject of the question. The task must be meaningful for the intended data conditions, and the method implementations should be sufficiently specified to reproduce what is being compared. If conclusions are intended to generalize beyond the benchmark data, those data conditions must represent the target use closely enough for that inference to be plausible.
Worked Formulations
Worked Example: Shared-Signal Recovery for a Discovery Team
A hypothetical team wants to compare two integration methods, Method A and Method B, for recovering features associated with a known shared disease signal from RNA, protein, and metabolite measurements. The intended users are investigators choosing a workflow for an initial discovery study. The target use is a cohort with all three modalities measured and a modest sample size, not a setting with extensive missingness.
A suitable question is: Among Method A and Method B, which more effectively recovers features carrying a known shared disease signal in modest-sized cohorts with complete RNA, protein, and metabolite measurements, to inform investigators choosing an initial multi-omics discovery workflow?
To check that the comparison is feasible, suppose the team plans 30 paired hypothetical data sets and will apply both methods to every data set. The number of method-by-data-set analyses is
This arithmetic checks workload; it does not define how successful recovery will be summarized. The paired data sets make the methods face the same generated information, which supports a direct comparison. The question also deliberately excludes incomplete-modality cohorts. A result from this benchmark should not be presented as evidence about that different use case.
Worked Example: Prediction When a Modality May Be Missing
Suppose a clinical group must predict a binary outcome using RNA and protein data, but protein measurements are unavailable for some patients. It is considering Method C, which can use incomplete modality inputs, and Method D, which requires complete measurements. The practical audience is a clinical data team deciding whether the more flexible method merits evaluation in its workflow.
A carefully bounded question is: How do Method C and Method D compare for predicting the binary outcome in cohorts where RNA is measured for everyone but protein is missing for a prespecified fraction of patients, for a clinical data team evaluating methods for incomplete multi-omics inputs? The wording makes missingness relevant to the task rather than treating it as an incidental data-cleaning detail. It also signals that the methods’ information requirements must be specified before the comparison is run.
For a simple planning check, assume the team will analyze 25 paired hypothetical cohorts with both methods, provided each method can produce the required prediction under the conditions in question. The planned number of method-by-cohort analyses is
If Method D cannot return predictions when protein is missing, the assumption that both methods can be compared on every cohort is false. The team must resolve that scope problem before analyzing results: for example, by defining a common eligible subset or by changing which method configurations are in scope. Quietly dropping difficult cohorts for only one method would answer a different, potentially unfair question.
Worked Example: Comparing an Integrated Method With a Baseline
A hypothetical method-development group proposes comparing an integrated feature-ranking method with an RNA-only baseline. The scientific task is to rank features that are known, in the generated data, to carry a shared signal across RNA and protein. The intended audience is method developers deciding whether integration adds value for this task, not clinicians selecting a treatment.
A prespecified question could be: For ranking features that carry a known shared signal across RNA and protein, how does the integrated method compare with the RNA-only baseline in cohorts with both modalities measured and moderate cross-omics dependence, for method developers assessing the value of integration?
Suppose the plan includes 40 paired hypothetical data sets and the two approaches are each applied once to every data set. The total number of method-by-data-set analyses is
Because the task concerns a shared signal, an RNA-only baseline is informative: it asks whether adding the second modality helps under the stated conditions. It does not establish whether the integrated method is preferable for every task, including tasks driven by modality-specific signals. The audience and task make this boundary explicit.
Why the Specification Matters
The need for a well-formed question follows from a simple logic of comparison. A claim about one method being preferable must be relative to another method, in a defined task, over a defined domain of data, for a defined purpose. Remove any one element and the claim becomes underdetermined. Without named methods, the comparator may change. Without data conditions, “performs well” has no stable scope. Without a task, a method may be judged against an objective it was not designed to meet. Without an audience or decision, it is unclear what practical conclusion the comparison is meant to support.
This is a design justification, not a mathematical guarantee of generalizability. Specifying a target domain does not prove that a benchmark represents it; that requires defensible data assumptions and evidence. Likewise, prespecification does not make an unfair comparison fair if methods receive different information, tuning effort, or preprocessing opportunities. It makes those choices visible and therefore reviewable.
Keep the question stable once results are available. If results reveal a useful additional task or an unexpected limitation, a follow-up question may be warranted. But changing the target conditions or intended task after seeing which method benefits can turn a planned comparison into a post hoc claim. Report the original question and distinguish any exploratory follow-up.
Diagnostics, Alternatives, and Limits
Before accepting a draft question, test it against likely failure modes:
- Vagueness: Terms such as “robust,” “best,” or “realistic” appear without identifying what conditions they refer to.
- Unmatched information: One method receives measurements or labels unavailable to another, although the question implies a like-for-like comparison.
- Task-condition mismatch: The task requires modalities that the target setting does not reliably measure.
- Unbounded claims: A narrow benchmark is described as establishing a universal ranking across diseases, cohorts, and tasks.
- Audience drift: A method-development result is presented as a clinical recommendation without evidence addressing that decision.
A benchmark question is not the only useful comparison format. A real-cohort validation can assess methods on observed data but may have limited control over the underlying truth. A simulation benchmark can specify known features of the data-generating process, but its conclusions depend on whether those conditions are relevant. A focused ablation can isolate the contribution of a component, while a broad leaderboard can compare many methods across a defined collection of tasks. These approaches answer different questions; none automatically substitutes for a clearly scoped target.
The question also has limits. It cannot establish that a method is causally informative, clinically beneficial, or transportable to a new population merely because it performs well in a benchmark. It cannot remove uncertainty about whether hypothetical conditions represent future data. Those conclusions require suitable designs and evidence beyond the wording of the question.
A Practical Formulation Sequence
State what choice the evidence should inform and identify the intended audience.
Describe the scientific objective and the output expected from the methods.
Describe the data setting to which the answer is intended to apply, including relevant modality coverage and cohort characteristics.
Name methods, versions, and baselines sufficiently to avoid changing the competitors after results are known.
Check that the methods can address the task under the stated conditions and that the planned comparison treats them fairly.
The resulting sentence should be concise enough to communicate, but detailed enough to constrain interpretation. Keep the performance estimand and data-generation choices open for their own design steps; do not let those details disappear, but do not confuse them with the question they are meant to serve.
Check Your Understanding
Answer each question, then compare your reasoning with the brief solutions.
- A draft asks, “Which method is most robust?” Name two missing elements that prevent a clear benchmark question.
- Why should a benchmark for outcome prediction with sometimes-missing protein data identify that missingness in its target conditions?
- A team compares three methods on 18 paired hypothetical data sets, applying every method to every set. How many method-by-data-set analyses are planned?
- What is the difference between a benchmark question and a performance estimand?
- Why should a narrow benchmark result not be described as a universal method ranking?
Solutions. (1) The draft does not specify what “robust” means in terms of a scientific task or data conditions; it may also omit the methods and intended audience. (2) Missingness can determine whether a method can be used and whether the comparison represents the intended clinical workflow, so it is part of the scope rather than a minor detail. (3) \(3\times18=54\) method-by-data-set analyses. (4) The question defines the comparison’s methods, task, target conditions, and audience; the estimand is a numerical summary used to represent a particular aspect of performance. (5) The result is supported only for the methods, task, and conditions represented; unstudied settings may differ in ways that change performance.